Humanetics Launches Phase 2 Lung Cancer Trial

New investigator-led study to explore potential of BIO 300 drug candidate

Mar. 31, 2026 at 5:13pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of a human lung, revealing the intricate network of veins and airways that make up this vital organ. The image conceptually represents the complex biology underlying lung cancer and the potential for new treatments to improve patient outcomes.An innovative drug candidate aims to enhance radiation therapy for lung cancer patients, offering new hope in the fight against this deadly disease.Minneapolis Today

Humanetics Corporation, a biopharmaceutical company, has announced the initiation of an investigator-led Phase 2 clinical trial evaluating its drug candidate BIO 300 in patients with non-small cell lung cancer. The trial will be conducted at a leading cancer research center to further explore the potential of BIO 300 as a treatment option.

Why it matters

Lung cancer is one of the most prevalent and deadly forms of cancer, making the development of new treatment options a critical priority. This investigator-initiated trial represents an important step in assessing the efficacy of Humanetics' BIO 300 compound, which has shown promise in preclinical studies for its ability to enhance the effects of radiation therapy.

The details

The Phase 2 trial will enroll patients with non-small cell lung cancer to evaluate the safety and efficacy of BIO 300 in combination with standard-of-care radiation therapy. Humanetics is providing the investigational drug and supporting the trial, which will be led by researchers at a prominent cancer research institution.

  • The trial was initiated on March 31, 2026.

The players

Humanetics Corporation

A biopharmaceutical company focused on developing novel therapies, including the BIO 300 drug candidate for cancer treatment.

Got photos? Submit your photos here. ›

What’s next

Humanetics expects the Phase 2 trial to provide valuable data on the potential of BIO 300 to improve outcomes for patients with non-small cell lung cancer when used in combination with radiation therapy.

The takeaway

This investigator-initiated trial represents an important advancement in Humanetics' efforts to develop new treatment options for one of the most challenging forms of cancer. The results of this study could pave the way for further clinical development of BIO 300 and offer hope to lung cancer patients.